Objective: To evaluate the association between exposure to oral corticosteroids and future healthcare resource utilization and costs for patients with systemic lupus erythematosus. Methods: Adults diagnosed with systemic lupus erythematosus (index date) between 1 January 2008 and 30 June 2013 and naive to oral corticosteroids with continuous health plan enrollment for !6 months pre-and !5 years post-index were identified from a large health plan claims database. Per-patient monthly average daily dose of oral corticosteroids (prednisone or its equivalent) was calculated for the first 2 years post-index to categorize patients into four steroid exposure cohorts: low ( 5 mg/day), medium (6-20 mg/day), high (>20 mg/day) and no steroids. Differences in healthcare resource utilization and total healthcare costs during the third year post-index across corticosteroid exposure cohorts were modeled with adjustment for baseline characteristics. Results: The study included 18,618 systemic lupus erythematosus patients (163 high dose, 1127 medium dose, 6717 low dose and 10,611 no steroids). Compared to low-dose corticosteroid users, high-dose corticosteroid users were more likely to have emergency room visits (39.3% vs. 29.7%; p ¼ 0.0085) and to be hospitalized (21.5% vs. 12.3%; p ¼ 0.0005). After adjustment for baseline characteristics, they also had significantly greater average annual total healthcare costs (US$60,366 vs. US$18,777; p < 0.0001). A 1 mg increase in corticosteroid average daily dose was associated with 1.07 times the average annual costs after adjusting for baseline characteristics (p < 0.0001). Conclusion: Long-term high-dose oral corticosteroid use was associated with significantly greater future healthcare resource utilization and costs. Judicious reduction in daily steroid dose may decrease the imminent economic burden associated with high-dose steroid use in systemic lupus erythematosus. Lupus (2018) 27, 1799-1809.
Introduction
Systemic lupus erythematosus (SLE) is a serious chronic autoimmune disease characterized by widespread inflammation in multiple organs. 1, 2 It occurs primarily in young women of child-bearing age. 1, 3 According to estimates of the Lupus Foundation of America, 1.5 million Americans have a form of lupus and more than 16,000 new cases are reported every year. 4 SLE is associated with compromised health-related quality of life (HRQoL) and significant economic burden, with mean annual direct costs reported to range from US$13,735 to US$20,926 per person in the United States of America (USA) (adjusted to 2009 US dollars).
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Mean annual medical costs for patients with SLE are reported to be three to four times greater than those for people without SLE. 15 Current treatment options manage the symptoms of disease and reduce the number and severity of flares, with corticosteroids (CSs) often being the cornerstone of treatment. [16] [17] [18] [19] Despite this, few studies have evaluated the impact of CS dose on healthcare resource utilization (HCRU) and costs among SLE patients in the USA. They have reported greater doses of CSs are associated with increased risk and incidence of various CS-associated adverse events and greater annual HCRU and costs. [20] [21] [22] [23] [24] Although the clinical burden and toxicity of CSs are well established in the literature, none of these studies have evaluated the HCRU and costs among SLE patients newly initiating oral CS therapy and receiving long-term highdose, medium-dose or no CSs versus low-dose oral CSs. Published large administrative database studies that evaluated CS-associated HCRU and costs in SLE also used relatively older data, 21, 23 while US payers are interested in recent data. As CSs are commonly prescribed in SLE patients and many patients take them chronically, it is important to generate evidence on the current clinical and economic burden associated with long-term CS use. Thus, the goal of this study was to evaluate the association between exposure to oral CSs measured over 24 months and future HCRU and costs in commercially insured SLE patients newly initiating oral CS treatment in the USA.
Patients and methods

Data source
This observational, retrospective cohort study was conducted using the IQVIA PharMetrics Plus (PMTXþ) Health Plan Claims Database from 1 July 2007 to 30 June 2016. This database comprises adjudicated medical and pharmacy claims for more than 150 million unique health plan members across the USA, providing a diverse representation of geography, employers, payers and providers. Data elements include inpatient and outpatient diagnoses and procedures, retail and mail order prescription records, pharmacy and medical benefit (co-pay, deductible) information, inpatient stay and provider details, demographic variables, product type, payer type, and start and stop dates of health-plan enrollment. Amounts charged by the providers and allowed and paid by the health plans are available for all services rendered. The database is nationally representative of the US commercially insured population in terms of age and sex. Patients in each three-digit zip code and every metropolitan statistical area of the USA are included, with data from 90% of US hospitals, 80% of all US doctors and representation from 85% of the Fortune 100 companies. All data are compliant with the Health Insurance Portability and Accountability Act to protect patients' privacy.
Sample selection
Patients aged !18 years with !2 non-same-day medical claims with a diagnosis of SLE (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code: 710.0x) between 1 January 2008 and 30 June 2013 (selection period) were identified in the database. The date of the first observed SLE diagnosis code (!2 non-same-day medical claims with a diagnosis of SLE (ICD-9 710.0x) were required) was defined as the index date (prevalent SLE population). For inclusion, patients needed to have continuous health plan enrollment for !180 days immediately preceding the index date (pre-index period) and !1080 days immediately following the index date (post-index period). Patients were excluded from the study if they had !1 pharmacy claim for oral steroids during the 180-day pre-index period; were aged !65 years and not covered by Medicare Risk, had Medicare Cost coverage or State Children's Health Insurance Program; or had data quality issues (missing drug quantity information or invalid year of birth, sex, or health plan enrollment dates).
Defining CS exposure groups
The first 2 years of the post-index period were used to create oral CS exposure groups for comparison (exposure period), whereas the third year of the post-index period was used to evaluate outcome measures. Three of the four exposure groups of interest were based on evidence of !1 pharmacy claim for an oral CS (betamethasone, budesonide, cortisone acetate, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisone or triamcinolone) during the exposure period and following their first SLE diagnosis. The first oral CS prescription or administration was defined as the patient's treatment index date. All patients with no evidence of oral CSs in the exposure period formed the fourth, 'no-steroid user' cohort and retained their SLE diagnosis-based index dates.
To account for the length of exposure as well as variable dosing, patients' average daily dose (ADD) of prednisone (the most commonly used oral CS in SLE patients) for each of the first 24 months postindex was calculated using the following formula derived from pharmacy claims: (strength x quantity)/days supply.
The per-patient average monthly ADD was then calculated for the 24-month period, and the resultant values were used to categorize patients into . low dose, defined as 5mg/day; . medium dose, defined as 6-20mg/day; and . high dose, defined as >20mg/day.
ADDs of other oral CSs (e.g. methylprednisolone) were converted into the prednisone equivalent. 25 
Study measures
All-cause HCRU and all-cause healthcare costs were evaluated in the post-index period during the third year. HCRU included the mutually exclusive categories of pharmacy services (Rx), emergency room (ER) visits, outpatient (OP) visits and inpatient (IP) visits. Costs were assessed for each of these HCRU services. Only direct healthcare costs for services covered by the patient's insurance benefit were reported, using allowed amounts on the claims, which represented the contracted reimbursable amount for covered medical services or supplies that the health plan agrees to pay to service providers. Costs were converted to 2016 US dollars using the medical component of the Consumer Price Index.
Patient demographics and baseline clinical characteristics were identified during the pre-index period. These included age at index date, sex, health plan type, payer type, region, index year, physician specialty (that recorded the SLE diagnosis), rheumatology visit, primary care physician (PCP) visit, hematology visit, nephrology visit, Charlson Comorbidity Index (CCI) score, comorbidities, concomitant medications (non-steroidal anti-inflammatory drugs (NSAIDs), anti-malarials and immunosuppressants, for example, cyclophosphamide, mycophenolate mofetil, azathioprine, cyclosporine, tacrolimus), total medical costs and total pharmacy costs.
Statistical analyses
For categorical measures, data were reported as the frequency (number of cases (N)) and the percentage of total patients observed in each category. For continuous variables, data were reported as the mean, SD and median. Differences in the distribution of these variables were tested for statistical significance using the chi-squared test for categorical variables and the non-parametric Wilcoxon ranksum test for continuous variables. A p-value 0.05 was considered statistically significant. Generalized linear modelling (with a log link function and gamma error term distribution) was used to evaluate differences in total healthcare costs during the third year post-index among CS exposure cohorts. Models were adjusted for age, gender, CCI score, cardiovascular disease (e.g. acute myocardial infarction, coronary atherosclerosis, aneurysm, pulmonary embolism, pericarditis, valve disorders, cardiomyopathy, tachycardia, atrial fibrillation, congestive heart failure, embolism) renal disease (e.g. glomerulonephritis, nephrotic syndrome, nephritis, nephropathy, acute kidney failure, chronic kidney disease, end state renal disease, renal failure, renal sclerosis), pre-index total medical costs and pre-index use of prescription NSAIDs and anti-malarial agents. These specific variables were selected for adjustment as they confound the association between steroid dose and HCRU/costs; furthermore, they have been previously demonstrated to be associated with HCRU and costs in SLE.
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Results
Study attrition
In total, 109,817 patients were initially identified as having evidence of SLE, of whom 91,199 (83%) were excluded for the reasons listed in Figure 1 . The remaining 18,618 patients included 163 highdose oral CS patients, 1127 medium-dose oral CS patients, 6717 low-dose oral CS patients and 10,611 no-steroid use patients (Table 1) .
Low-dose versus high-and medium-dose oral CSs Baseline characteristics
Compared with patients receiving low-dose CSs, patients receiving high-dose CSs were younger (46 vs. 43 years; p ¼ 0.0002), had a higher risk of renal disease (4.0% vs. 12.9%; p < 0.0001) and had greater mean pre-index total medical costs (US$5997 vs. US$11,977; p ¼ 0.0013). Compared with patients receiving low-dose CSs, patients receiving medium-dose CSs were also younger (46 vs. 44 years; p < 0.0001), had a higher risk of renal disease (4.0% vs. 10.2%; p < 0.0001) and had higher mean pre-index total medical costs (US$5,997 vs. US$9467; p < 0.0001). Table 1 provides additional details on the baseline characteristics of patients eligible for inclusion into our study.
Unadjusted HCRU and costs in the third year post-index A significantly greater percentage of patients receiving high-dose oral CS used ER services (39.3% vs. 29.7%; p ¼ 0.0085) and had ! 1 IP hospitalization (21.5% vs. 12.3%; p ¼ 0.0005) in the third year post-index compared to those receiving low-dose oral CS. Mean healthcare utilization (Rx, ER, OP and IP services) and mean all-cause total costs (US$60,366 vs. US$18,777; p < 0.0001) in the third year post-index were significantly greater for patients receiving high-dose oral CS. Table 2 and Figure 2 provide additional details.
A significantly greater percentage of patients receiving medium-dose oral CS used ER services (33.5% vs. 29.7%; p ¼ 0.0097) and had ! 1 IP hospitalization (17.6% vs. 12.3%; p < 0.0001) in the third year post-index compared to those receiving low-dose oral CS. Mean healthcare utilization (Rx, ER, OP and IP services) and mean all-cause total costs (US$31,095 vs. US$18,777; p < 0.0001) in the third year post-index were significantly greater for patients receiving medium-dose oral CS. Table 2 and Figure 2 provide additional details.
Multivariate models
In multivariate adjusted analysis, patients in the high-dose and medium-dose groups had 2.8 times (Table 3) . In a separate multivariate adjusted analysis, a 1 mg/day increase in steroid ADD increased the total all-cause healthcare costs by 1.07 times in the third year post-index (CR: 1.07, 95% CI: 1.062-1.074; p < 0.0001) (Figure 3 ).
Low-dose oral CSs versus no steroids Baseline characteristics
Compared with patients receiving low-dose CSs, patients in the no-steroid group were older (46 vs. 47 years; p ¼ 0.0003) with a lower proportion of patients having cardiovascular disease (13.5% vs.
10.8%; p < 0.0001) and infection (43.9% vs. 36.1%; p < 0.0001) in the 6-month pre-index period. Mean pre-index total medical and pharmacy costs were significantly lower for patients in the no-steroids group compared to those receiving low-dose CS (US$5195 vs. US$5997; p ¼ 0.0206 and US$1207 vs. US$1620; p < 0.0001, respectively). third year post-index were significantly lower for patients in the no-steroid group. Table 2 and Figure 2 provide additional details.
Multivariate model
In multivariate adjusted analysis, patients in the no-steroid group had 0.7 times (CR: 0.72, 95%
CI: 0.697-0.754) the average annual all-cause healthcare costs compared with those in the lowdose oral CSs group (Table 3) .
Discussion
In this study, patients in the high-dose and medium-dose oral CS groups had significantly greater (2.8 times and 1.7 times, respectively) average annual total healthcare costs compared with patients in the low-dose group. Patients in the nosteroids group had significantly lower (0.7 times) average annual total healthcare costs compared with patients in the low-dose group. Although previous studies have evaluated the economic burden of SLE associated with the use of oral CSs, 7, 8, 10, 11, 21 none of these studies have evaluated the impact of long-term exposure to CSs in SLE patients newly initiating oral CS treatment. Chen et al. 23 conducted a cross-sectional study among adult SLE patients using a large US insurance claims database and associated oral glucocorticoid use with greater annual HCRU and costs. Mean total healthcare costs during a 1-year follow-up period were reported to double from patients receiving low-dose glucocorticoid to patients receiving greater-dose glucocorticoid. 23 Compared to this study, our study included SLE patients new to oral CSs and evaluated the impact of long-term exposure to CSs on HCRU and costs (i.e. the first 2 years after SLE diagnosis were used to create CS exposure groups of interest and the third year post-index was used to evaluate the outcomes of interest). We also used different definitions that were agreed upon by rheumatology experts to identify high-, mediumand low-dose steroid use.
In our study sample, significantly greater percentage of patients receiving high-dose and medium-dose oral CSs consulted a nephrologist as their prescribing physician specialty, had renal disease, had greater number of nephrology visits and had significantly greater total medical costs in the pre-index period compared with those receiving low-dose oral CSs. Patients in the non-steroid group had significantly lower rheumatology visits, PCP visits and total medical and pharmacy costs in the pre-index period compared with those receiving low-dose oral CSs. Therefore, it was required to adjust for baseline characteristics, including pre-index medical costs and the CCI, to account for the covariate imbalance that exists when evaluating the association between steroid dose and HCRU/costs.
Compared to patients receiving low-dose oral CSs, a significantly greater percentage of patients receiving high-dose and medium-dose oral CSs used ER services and had !1 IP hospitalization with a longer mean length of stay in the third year post-index. On the other hand, a significantly lower percentage of patients in the non-steroid group used ER services, had !1 IP hospitalization and had a shorter mean length of hospital stay compared with those receiving low-dose oral CSs. Patients receiving CSs may need more regular monitoring, which may result in increased HCRU. 20, 26 More frequent ER visits and hospitalizations for patients who received greater CS doses may be attributed to greater disease severity, flares, worse general health status or treatment of adverse events. 19, 27, 28 The International Task Force for SLE recommends prescription of the lowest glucocorticoid dose needed for disease control and to withdraw glucocorticoid completely, if possible. 29 In addition, duration of exposure to CSs should be minimized. 30 Pre-existing comorbidities that may increase the risk of experiencing CS-related adverse events in the future should be evaluated prior to initiating CS therapy. 30 These actions may help reduce complications and economic burden associated with CS use for SLE patients and may improve HRQoL. 31 Steroid-sparing agents can accelerate the process of decreasing steroid requirements in SLE patients, yet tolerable and effective treatment options are limited. Treatment options that will help decrease CS use in SLE patients and improve their clinical, economic and HRQoL outcomes are needed.
Antimalarial use is lower in our cohort (22.1-33.4%) in comparison to other cohorts. For example, between 61-83% of SLE patients in the Lupus in Minorities, Nature versus Nurture (LUMINA) cohort reported hydroxychloroquine use. 32 In a Medicaid administrative database study of patients with SLE receiving immunosuppressive therapy (i.e. mycophenolate mofetil, azathioprine or cyclophosphamide), 30.1-54.4% were on hydroxychloroquine. 33 The differences in antimalarial treatment utilization among the different cohorts are likely due to differences in the patient samples included in the studies. The LUMINA cohort was primarily recruited from rheumatology clinics and had to meet the American College of Rheumatology definition of SLE for inclusion. In contrast, we identified SLE patients based on a previously validated method using provider-reported ICD-9 diagnosis codes. The SLE Medicaid population also has a very different sociodemographic (including age, income, race/ethnicity) profile than our cohort. For instance, the mean age of our study cohort is 45 whereas the mean age of the Medicaid cohort is 35.
This study had several limitations. First, administrative claims datasets are not designed for the primary purpose of conducting research. The internal validity is typically not sufficient to make positive inferences of cause and effect. Second, the analytic focus was on patients who met the continuous observation criteria (6 months pre-index and 36 months post-index), with a potential to eliminate patients who may have different treatment patterns coincident with observation patterns. Results may not be generalizable to those without consistent access to care, for instance. Third, patients selected for one particular treatment rather than another may have very different characteristics. Some of these differences were measured in our study (such as age and sex) but some are not measurable or not available in the dataset (e.g. patient preferences). Fourth, treatments may not be captured within the dataset and there may be incomplete encounter histories for patients selected for this study. Fifth, medical billing codes used to indicate diagnoses and procedures are subject to nonclinical influences. Finally, although adjustment for relevant baseline characteristics in the multivariate modelling was done, the opportunity for residual confounding remains.
In conclusion, in a contemporary cohort of SLE patients new to oral CSs, high-and medium-dose CS use was associated with significantly greater future healthcare utilization and costs relative to low-dose steroid use, after adjustment for baseline demographic and clinical characteristics. No-steroid use was associated with significantly lower future healthcare utilization and costs relative to low-dose steroid use. Patients with SLE receiving CSs require greater resource use for disease and medication management. Minimizing the daily steroid use of SLE patients while concomitantly controlling their disease activity may reduce the looming economic burden associated with CS use.
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